A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

Phase 3

Terminated

• Conditions: Diabetes Mellitus

• Registration Number: NCT00287066
• Lead Sponsor: Pfizer

Brief Summary

To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes

Detailed Description

The study was terminated on Oct. 28, 2007. The protocol was undergoing implementation and methodological issues with major revisions that qualified this trial as a new trial. Pfizer decided to cancel new trials because of the decision to withdraw Exubera due to lack of market performance and not for safety reasons.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2006-02
• Study First Submitted: 2006-02-02
• Study First Submitted QC: 2006-02-02
• Study First Posted: 2006-02-06
• Study Completion: 2007-03
• Status Verified: 2007-04
• Last Update Submitted: 2008-02-20
• Last Update Posted: 2008-02-21

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Diabetes mellitus Type 1

Read More

Exclusion Criteria

• Asthma, COPD
• Smoking

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
18F-labeled glucose uptake in muscle

Secondary Outcome Measures

Name	Time	Method
Glucose turnover overnight Insulin pharmacokinetics

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇺🇸 Pittsburgh, Pennsylvania, United States